Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).
Description for laymen
This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).
JSON Data
{
"short_title": "MK-2870-015",
"data_mode": "900",
"data_mode_number": "000002389",
"official_title": "A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "gtThird",
"ctgov_number": "NCT06356311",
"eudract_number": null,
"general_contact_email": "oncostudy@ukdd.de",
"general_contact_phone": "+49 351-4587666",
"hauptpruefer_dd_name": "Prof. Dr. med. Gunnar Folprecht",
"description_laie_de": "In dieser Studie wird verglichen, wie sicher und wirksam Sacituzumab-Tirumotecan im Vergleich zur Behandlung nach Wahl des Arztes (TPC) bei Teilnehmern mit fortgeschrittenem/metastasiertem Adenokarzinom des Gastro\u00f6sophagus ist. Die prim\u00e4re Hypothese dieser Studie lautet, dass Sacituzumab-Tirumotecan der TPC in Bezug auf das Gesamt\u00fcberleben (OS) \u00fcberlegen ist.",
"description_laie_en": "This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).",
"description_expert_de": "In dieser Studie wird verglichen, wie sicher und wirksam Sacituzumab-Tirumotecan im Vergleich zur Behandlung nach Wahl des Arztes (TPC) bei Teilnehmern mit fortgeschrittenem/metastasiertem Adenokarzinom des Gastro\u00f6sophagus ist. Die prim\u00e4re Hypothese dieser Studie lautet, dass Sacituzumab-Tirumotecan der TPC in Bezug auf das Gesamt\u00fcberleben (OS) \u00fcberlegen ist.",
"description_expert_en": "This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 2,
"sub_cat_id": 5
}
